Skip to main content

Table 1 Baseline patient characteristics.

From: Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer

Overall

All patients enrolled(N = 115)

Age, years

53.53(±8.69)

Data for front-line treatment in this study

 The tumor origin

  Ovary

107 (93.0%)

  Fallopian tube

6 (5.2%)

  Peritoneum

1 (0.9%)

  unknown

1 (0.9%)

 Pathologic histology type

  Serous Tumors

108 (93.9%)

  High-grade

91 (84.3%)

  Low-grade

8 (7.4%)

  Unknown

9 (8.3%)

  Mucinous Tumors

1 (0.9%)

  Endometrioid Tumors

1 (0.9%)

  Clear Cell Tumors

4 (3.5%)

  Mixed epithelial tumors

1 (0.9%)

 FIGO stage

  I

1 (0.9%)

  II

4 (3.5%)

  III

97 (84.3%)

  IIIA

10 (10.3%)

  IIIB

10 (10.3%)

  IIIC

74 (76.3%)

  Unknown

3 (3.1%)

  IV

13 (11.3%)

  IVA

3 (23.1%)

  IVB

6 (46.2)

  Unknown

4 (30.7%)

Primary cytoreductive surgery

59 (51.3%)

Interval cytoreductive surgery

56 (48.7%)

Residual disease

 Optimal cytoreductive surgery

  No gross residual disease (R0)

50 (43.5%)

  <1 cm but visible residual disease

46 (40.0%)

  Suboptimal cytoreductive

16 (13.9%)

  Unknown

3 (2.6%)

Previous chemotherapy cycles

  < 6

16 (13.9%)

 6–9

92 (80.0%)

  > 9

2 (1.7%)

 Unknown

5 (4.3%)

The previous response status to platinum-based chemotherapy

 Platinum-refractory

36 (31.3%)

 Platinum-resistant relapse

31 (27.0%)

 Partially platinum- sensitive relapse

48 (41.7%)

Data before this study

CA125, U/ml

183.90 (72.27–430.65; 6.00–7135.00)

ECOG

 0

63 (54.8%)

 1

46 (40.0%)

 2

6 (5.2%)

  1. Data are shown as mean (±standard deviation) or median (IQR; range) or n (%). FIGO, International Federation of Gynecology and Obstetrics; ECOG, Eastern Cooperative Oncology Group